Aptose commences dosing first CLL patient in phase 1 study of CG-806
Category: #health  By Pankaj Singh  Date: 2019-07-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Aptose commences dosing first CLL patient in phase 1 study of CG-806

Initial data from the first two cohorts has demonstrated MYC inhibition in patients with acute myelodysplastic syndrome (MDS) and myeloid leukemia (AML).

The clinical-stage company Aptose Biosciences Inc. has reportedly announced that it has started phase 1a/b dose-escalation trial by dosing CG-806 to the patients with small lymphocytic lymphoma (SLL), non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL). CG-806 is the company’s highly potent, first-in-class pan-FLT3/pan-BTK inhibitor.

Apparently, the patients with small lymphocytic lymphoma (SLL), non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) who have failed or are intolerant to standard therapies have been dosed in the trial. Simultaneously, the company has successfully concluded the first two dose levels of the Phase 1b clinical study of MYC inhibitor APTO-253 and commenced dosing the third dose unit. Initial data from the first two cohorts has demonstrated MYC inhibition in patients with acute myelodysplastic syndrome (MDS) and myeloid leukemia (AML).

William G. Rice, Ph.D., Chief Executive Officer, Chairman and President, Aptose, reportedly expressed pleasure that the much anticipated first-in-human dosing with CG-806 has occurred and it has successfully started CG-806 oral dosing in a patient enduring CLL. CG-806 is a highly effective non-covalent inhibitor of all forms of FLT3 and BTK driver kinases which concurrently dominates multiple oncogenic signaling pathways on which cancer cells depend for survival, yet with a precision which evades targets typically linked with toxicity, he further added.

Dr. Rice further noted that the organization has completed dosing of the first two cohorts in a Phase 1b trial with its APTO-253 MYC inhibitor, with just one patient needed in each cohort. Both subjects completed the 28-day cycle and felt reductions of MYC gene expression in their peripheral blood cells, a vital finding as MYC performs a central role in the oncogenic process and the third dose unit at 66mg/m2 has been enrolling effectively for a total of three planned subjects, he added.

Source credit: https://ir.aptose.com/news-releases/news-release-details/aptose-doses-first-cll-patient-phase-1-study-cg-806-and-doses



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...